Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 294

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

Open access
Videtic, Gregory M., Paulus, Rebecca, Singh, Anurag K., Chang, Joe Y., Parker, William, Olivier, Kenneth R., Timmerman, Robert D., Komaki, Ritsuko R., Urbanic, James J., Stephans, Kevin L., Yom, Sue S., Robinson, Clifford G., Belani, Chandra P., Iyengar, Puneeth, Ajlouni, Munther I., Gopaul, Darindra D., Gomez Suescun, Jorge B., McGarry, Ronald C., Choy, Hak, Bradley, Jeffrey D.·2019·International Journal of Radiation Oncology*Biology*Physics

Abstract

Purpose/Objective(s): To present long-term results of RTOG 0915/NCCTG N0927, a randomized lung stereotactic body radiotherapy (SBRT) trial of 34 Gy in 1 fraction versus 48 Gy in 4 fractions. Materials/Methods: This was a phase II multicenter study of medically inoperable non-small cell lung cancer patients with biopsy-proven peripheral T1 or T2 N0M0 tumors, with 1-year toxicity rates as primary endpoint and selected failure and survival outcomes as secondary endpoints. The study opened in September 2009 and closed in March 2011. Final data were analyzed through May 17, 2018. Results: Eighty four of 94 patients accrued were eligible for analysis: 39 in arm 1 and 45 in arm 2. Median follow-up time was 4.0 years for all patients, and 6.0 years for those alive at analysis. Rates of grade 3 and higher toxicity were 2.6% in arm 1 and 11.1% in arm 2. Median survival times (in years) for 34 Gy and 48 Gy were 4.1 vs. 4.6, respectively. Five-year outcomes as % (95% CI) for 34 Gy and 48 Gy were: primary tumor failure rate of 10.6 (3.3, 23.1) vs. 6.8 (1.7, 16.9); overall survival of 29.6 (16.2, 44.4) vs. 41.1 (26.6, 55.1); and progression-free survival of 19.1 (8.5, 33.0) vs. 33.3 (20.2, 47.0); respectively. Distant failure as the sole failure or a component of first failure occurred in 6 patients (37.5%) in the 34 Gy arm and in 7 (41.2%) in the 48 Gy arm. Conclusions: No excess in late-appearing toxicity was seen in either arm. Primary tumor control rates at 5 years were similar by arm. Median survival times of 4 years for each arm suggest similar efficacy pending any larger studies appropriately powered to detect survival differences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2018.11.051

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Metadata

Authors
Videtic, G. M., Paulus, R., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Timmerman, R. D., Komaki, R. R., Urbanic, J. J., Stephans, K. L., Yom, S. S., Robinson, C. G., Belani, C. P., Iyengar, P., Ajlouni, M. I., Gopaul, D. D., Gomez Suescun, J. B., McGarry, R. C., Choy, H., & Bradley, J. D.
Venue
International Journal of Radiation Oncology*Biology*Physics
Publisher
Elsevier BV
Published
2019-04
Volume
103
Issue
5
Pages
1077-1084
ISSN
0360-3016 (ISSN-L)
OpenAlex
W2756847895
Cited by
294
References
5
FWCI
18.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1016/j.ijrobp.2018.11.051
The paper
Videtic, G. M., Paulus, R., Singh, A. K., Chang, J. Y., Parker, W., Olivier, K. R., Timmerman, R. D., Komaki, R. R., Urbanic, J. J., Stephans, K. L., Yom, S. S., Robinson, C. G., Belani, C. P., Iyengar, P., Ajlouni, M. I., Gopaul, D. D., Gomez Suescun, J. B., McGarry, R. C., Choy, H., & Bradley, J. D. (2019). Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2018.11.051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.